Mineralys Therapeutics, Inc. (MLYS) — Stock Score Summary

Mineralys Therapeutics, Inc. (MLYS) has a MoatMap StockRank of 11/100 based on Quality (35/100), Value (38/100), and Momentum (20/100) factor scores. The current signal is STRONG SELL. Mineralys Therapeutics is a clinical-stage biotech company. It is a pre-revenue binary-event play that does not meet our criteria for predictable owner earnings, high ROIC, or structural pricing power.

Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for hypertension and cardiorenal diseases, with its lead candidate lorundrinerant. Its proprietary drug candidate targets a novel mechanism of action (aldosterone synthase inhibition) for uncontrolled hypertension, addressing a significant unmet medical need. The company is developing a potential first-in-class treatment that could offer a new therapeutic option for patients with high blood pressure and related conditions.

Key Financial Metrics

Price$24.18
Market Cap$2.6B
P/E (Forward)-11.95
Price/Book3.16
Return on Equity-31.0%
Return on Invested Capital-26.4%
Gross Margin0.0%
Operating Margin0.0%
Free Cash Flow$-79M

Mineralys Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Mineralys Therapeutics, Inc.’s (MLYS) StockRank?
MoatMap’s StockRank for Mineralys Therapeutics, Inc. (MLYS) is 11/100, with a Strong Sell signal. It is a composite of Quality (35), Value (38), and Momentum (20) factor ranks across MoatMap’s 19,000+ stock universe.
Does Mineralys Therapeutics, Inc. have an economic moat?
Mineralys Therapeutics, Inc. (MLYS) has a Quality factor score of 35/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Mineralys Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Mineralys Therapeutics, Inc. (MLYS) is Strong Sell, based on a StockRank of 11/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Mineralys Therapeutics, Inc. in?
Mineralys Therapeutics, Inc. (MLYS) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksMLYS deep dive reportAI ChampionsHow we score stocksSense-check another stock